CAMP4 Therapeutics Corporation
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $301.5M
- Price
- $4.46
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.09%
- Volume
- 395.7K
About
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
Quick stats
Shares outstanding62.8M
Computed float28.8M
Float / shares46.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001736730
Websitehttps://www.camp4tx.com
AI Summary
AI-generated1/27
majorbullishearnings
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
CAMP4 reported Q2 2026 financial results with a net loss of $33.5 million, primarily driven by a $20.9 million non-cash derivative valuation change, while simultaneously securing regulatory clearance in Australia and Argentina for a Phase 1/2 trial of CMP-002.
The company closed the second tranche of a private placement, raising $50.1 million in gross proceeds, which extends its cash runway through the end of 2028.
Management anticipates initiating the first-in-human trial for SYNGAP-1 related disorders in the fourth quarter of 2026, with regulatory filings already submitted in the EU and UK.
Red flags
- Total stockholders' equity swung to a deficit of approximately $0.7 million from a positive $47.7 million at year-end 2025